ArticleFrontiers in medicine2022
Risk Factors of Silicosis Progression: A Retrospective Cohort Study in China.
Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The Combined Role of Silanols and Oxidative Stress in Determining Engineered Stone Dust Toxicity.ACS organic & inorganic Au · 2026Article
- Tetrandrine slows disease progression on high-resolution computed tomography and lung function decline in artificial stone-associated silicosis: a retrospective cohort study.BMC pulmonary medicine · 2025Article
- A review of silicosis and other silica-related diseases in the engineered stone countertop processing industry.Journal of occupational medicine and toxicology (London, England) · 2025Review
- Burden of silicosis based on the Global Burden of Disease Study 2021: trend analysis of incidence, mortality, and disability-adjusted life years, and projections for the next 30 years.Journal of thoracic disease · 2025Article
- Results of 15 years of extended follow-up of the German porcelain workers cohort study: lung cancer and silicosis.Frontiers in public health · 2025Article
- Silicosis: from pathogenesis to therapeutics.Frontiers in pharmacology · 2025Review
- Managing Silicosis in the United States: How I Do It.CHEST pulmonary · 2024Article
- Efficacy and safety of a whole lung lavage program for artificial stone silicosis.Journal of thoracic disease · 2024Article
- From Engineered Stone Slab to Silicosis: A Synthesis of Exposure Science and Medical Evidence.International journal of environmental research and public health · 2024Review
- Clinical efficacy of tetrandrine in artificial stone-associated silicosis: A retrospective cohort study.Frontiers in medicine · 2023Article
- Development and Validation of the Tuberculosis Risk Score for Smokers (TBRSS).International journal of environmental research and public health · 2022Article
- Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Silicosis poses a threat to workers' health due to the irreversible lung lesions. Design: A retrospective cohort study. Methods: A total of 259 patients [80 worked with artificial stone (AS), 179 with non-artificial stone (non-AS)] with confirmed silicosis were included in this study. Forty-one of AS and 91 of non-AS had approximately 2 years' follow-up records [lung function tests and high-resolution computer tomography (HRCT)]. Compared with the first records, increased, densified, or newly emerging lesions in lung HRCT images were judged as progression of the disease. Cox proportional hazards models were used to determine the risk factors. Kaplan-Meier survival curve and log-rank test were used to compare prognostic factors for cumulative risk of progression. Results: In 132 patients with median follow-up of 24.0 months (IQR, 13.8, 24.9), 66 patients showed progression, in them, 36 (87.8%) were from AS group and 30 (32.9%) from non-AS group. Working experience of AS processing (hazard ratio, 5.671; 95% CI, 3.048-10.550) and complicated silicosis in CT images (hazard ratio, 2.373; 95% CI, 1.379-4.082) were the main risk factors associated with progression. Forced vital capacity decreased after 1-year (241.5 vs. 55.2 mL) and 2-year (328.1 vs. 68.8 mL) follow-up in the two groups (AS vs. non-AS). History of anti-tuberculosis medication, chest oppression and pain, ground-glass opacity, pleural abnormalities, and restrictive pulmonary dysfunction were more frequently found on HRCT images in the AS group than non-AS group. Lung functions (DL Conclusion: Prevention and protection rules are needed to be enforced in the occupation involving AS processing; smoking may be associated with declined lung function in AS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.